ID   Calu-6
AC   CVCL_0236
SY   CaLu-6; CALU-6; Calu.6; Calu 6; Calu6; CALU6; CaLu-06
DR   BTO; BTO:0002235
DR   CLO; CLO_0002193
DR   EFO; EFO_0002152
DR   MCCL; MCC:0000125
DR   CLDB; cl636
DR   CLDB; cl638
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-56
DR   BioGRID_ORCS_Cell_line; 587
DR   BioSample; SAMN03473148
DR   BioSample; SAMN10987791
DR   cancercelllines; CVCL_0236
DR   CCRID; 1101HUM-PUMC000813
DR   CCRID; 3101HUMTCHu144
DR   Cell_Model_Passport; SIDM00921
DR   ChEMBL-Cells; CHEMBL3307639
DR   ChEMBL-Targets; CHEMBL614535
DR   CLS; 300135
DR   Cosmic; 724859
DR   Cosmic; 929969
DR   Cosmic; 933575
DR   Cosmic; 934466
DR   Cosmic; 934542
DR   Cosmic; 1071885
DR   Cosmic; 1089230
DR   Cosmic; 1146874
DR   Cosmic; 1176611
DR   Cosmic; 1434959
DR   Cosmic; 1995360
DR   Cosmic; 2668262
DR   Cosmic-CLP; 724859
DR   DepMap; ACH-000264
DR   DSMZ; ACC-734
DR   DSMZCellDive; ACC-734
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 724859
DR   GEO; GSM108805
DR   GEO; GSM108806
DR   GEO; GSM253341
DR   GEO; GSM434325
DR   GEO; GSM513938
DR   GEO; GSM514319
DR   GEO; GSM794263
DR   GEO; GSM843487
DR   GEO; GSM886916
DR   GEO; GSM887982
DR   GEO; GSM1374435
DR   GEO; GSM1374436
DR   GEO; GSM1669659
DR   IARC_TP53; 119
DR   IARC_TP53; 21265
DR   ICLC; HTL97003
DR   IGRhCellID; Calu6
DR   KCLB; 30056
DR   LiGeA; CCLE_215
DR   LINCS_LDP; LCL-1626
DR   Lonza; 1139
DR   NCBI_Iran; C431
DR   PharmacoDB; Calu6_180_2019
DR   PRIDE; PXD025499
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0236
DR   PubChem_Cell_line; CVCL_0236
DR   Wikidata; Q54808427
RX   PubMed=1855224;
RX   PubMed=2388294;
RX   PubMed=3129183;
RX   PubMed=3335022;
RX   PubMed=3518877;
RX   PubMed=3940644;
RX   PubMed=6148444;
RX   PubMed=6935474;
RX   PubMed=7459858;
RX   PubMed=7834619;
RX   PubMed=7972006;
RX   PubMed=8385084;
RX   PubMed=12068308;
RX   PubMed=12794755;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20679594;
RX   PubMed=22460905;
RX   PubMed=22961666;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29681454;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://www.mskcc.org/research-advantage/support/technology/tangible-material/calu-06
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/c/cell-lines-detail-473.html
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Population: Caucasian.
CC   Doubling time: 26 hours (Note=In RPMI 1640 + 10% FBS), 32 hours (Note=In ACL-3), 41 hours (Note=In ACL-3+BSA) (PubMed=3940644); 31.9 hours (PubMed=29681454); ~2 days (CLS=300135); ~72 hours (DSMZ=ACC-734).
CC   HLA typing: A*01:01,01:01; B*08:01,35:08; C*07:01,07:01 (PubMed=26589293).
CC   Karyotypic information: Has lost chromosome Y.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Lys (c.180_181TC>CA) (c.180_181delinsCA); Zygosity=Heterozygous (PubMed=1855224; PubMed=12068308; PubMed=12794755; ATCC; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (PubMed=1855224; PubMed=12794755; ATCC; Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.17%; Native American=0.95%; East Asian, North=0.74%; East Asian, South=0%; South Asian=0%; European, North=66.06%; European, South=32.08% (PubMed=30894373).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC; CLS; Cosmic-CLP; DSMZ; KCLB; PubMed=20679594; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 13
ST   D18S51: 12,16
ST   D19S433: 13
ST   D21S11: 31
ST   D2S1338: 17,26
ST   D3S1358: 16
ST   D5S818: 11
ST   D7S820: 10
ST   D8S1179: 10,14
ST   FGA: 22
ST   Penta D: 13
ST   Penta E: 5,14
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 44
//
RX   PubMed=1855224;
RA   Lehman T.A., Bennett W.P., Metcalf R.A., Welsh J.A., Ecker J.,
RA   Modali R.V., Ullrich S., Romano J.W., Appella E., Testa J.R.,
RA   Gerwin B.I., Harris C.C.;
RT   "p53 mutations, ras mutations, and p53-heat shock 70 protein complexes
RT   in human lung carcinoma cell lines.";
RL   Cancer Res. 51:4090-4096(1991).
//
RX   PubMed=2388294; DOI=10.1093/jnci/82.17.1420;
RA   McLemore T.L., Litterst C.L., Coudert B.P., Liu M.C., Hubbard W.C.,
RA   Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.;
RT   "Metabolic activation of 4-ipomeanol in human lung, primary pulmonary
RT   carcinomas, and established human pulmonary carcinoma cell lines.";
RL   J. Natl. Cancer Inst. 82:1420-1426(1990).
//
RX   PubMed=3129183;
RA   Hubbard W.C., Alley M.C., McLemore T.L., Boyd M.R.;
RT   "Evidence for thromboxane biosynthesis in established cell lines
RT   derived from human lung adenocarcinomas.";
RL   Cancer Res. 48:2674-2677(1988).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=3940644;
RA   Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.;
RT   "Growth of cell lines and clinical specimens of human non-small cell
RT   lung cancer in a serum-free defined medium.";
RL   Cancer Res. 46:798-806(1986).
//
RX   PubMed=6148444; DOI=10.1093/jnci/73.4.801;
RA   Morstyn G., Russo A., Carney D.N., Karawya E., Wilson S.H.,
RA   Mitchell J.B.;
RT   "Heterogeneity in the radiation survival curves and biochemical
RT   properties of human lung cancer cell lines.";
RL   J. Natl. Cancer Inst. 73:801-807(1984).
//
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
//
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
//
RX   PubMed=7834619;
RA   Washimi O., Nagatake M., Osada H., Ueda R., Koshikawa T., Seki T.,
RA   Takahashi T., Takahashi T.;
RT   "In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations
RT   preferentially in non-small cell lung cancers.";
RL   Cancer Res. 55:514-517(1995).
//
RX   PubMed=7972006; DOI=10.1073/pnas.91.23.11045;
RA   Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P.,
RA   Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H.,
RA   Harris C.C.;
RT   "Mutations and altered expression of p16INK4 in human cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994).
//
RX   PubMed=8385084; DOI=10.1111/j.1349-7006.1993.tb02851.x;
RA   Suzuki S., Takahashi T., Nakamura S., Koike K., Ariyoshi Y.,
RA   Takahashi T., Ueda R.;
RT   "Alterations of integrin expression in human lung cancer.";
RL   Jpn. J. Cancer Res. 84:168-174(1993).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=12794755; DOI=10.1002/ijc.11184;
RA   Endoh H., Yatabe Y., Shimizu S., Tajima K., Kuwano H., Takahashi T.,
RA   Mitsudomi T.;
RT   "RASSF1A gene inactivation in non-small cell lung cancer and its
RT   clinical implication.";
RL   Int. J. Cancer 106:45-51(2003).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20679594; DOI=10.1093/jnci/djq279;
RA   Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.;
RT   "Lung cancer cell lines as tools for biomedical discovery and
RT   research.";
RL   J. Natl. Cancer Inst. 102:1310-1321(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112;
RA   Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P.,
RA   Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F.,
RA   Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J.,
RA   Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L.,
RA   Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D.,
RA   Heymach J.V.;
RT   "Proteomic profiling identifies dysregulated pathways in small cell
RT   lung cancer and novel therapeutic targets including PARP1.";
RL   Cancer Discov. 2:798-811(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29681454; DOI=10.1016/j.cell.2018.03.028;
RA   McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R.,
RA   Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M.,
RA   Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L.,
RA   Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J.,
RA   DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A.,
RA   Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S.,
RA   Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G.,
RA   Posner B.A., Minna J.D., Kim H.S., White M.A.;
RT   "Chemistry-first approach for nomination of personalized treatment in
RT   lung cancer.";
RL   Cell 173:864-878.e29(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//